A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma

A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma

Background & aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible patients who had progressed or were intolerant to sorafenib received...

Full description

Bibliographic Details
Main Authors: Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JHEP Reports
Subjects:
Capmatinib
Spartalizumab
Hepatocellular carcinoma
MET
anti-programmed death-ligand 1
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555924000223

Internet

http://www.sciencedirect.com/science/article/pii/S2589555924000223

Similar Items